Lymphoma section

Featured Lymphoma Content

Recent Advances in Management of Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the clinical treatment options for patients with relapsed Hodgkin lymphoma and anaplastic large cell lymphoma.

Lymphoma News and Features

Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma

Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma

A review of therapy options for relapsed/refractory DLBCL and FL compared SCT with chemotherapy/immunotherapy and experimental regimes. Patients fared better with SCT than other treatment modalities.

Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress

Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress

A retrospective evaluation of patients treated at a tertiary cancer center demonstrated that patients with Hodgkin lymphoma experienced periods of actionable distress in survivorship, despite a low overall distress burden.

Risk Factors for Higher-Grade Transformation in Marginal Zone Lymphomas Identified

Risk Factors for Higher-Grade Transformation in Marginal Zone Lymphomas Identified

In a retrospective evaluation, investigators sought to identify risk factors for higher-grade transformation in patients with marginal zone lymphomas.

Cost of Brentuximab Vedotin as First-Line Therapy for Advanced Hodgkin Lymphoma Prohibitive

Cost of Brentuximab Vedotin as First-Line Therapy for Advanced Hodgkin Lymphoma Prohibitive

Although brentuximab vedotin offers clinical benefit over bleomycin in first-line treatment of adults with advanced Hodgkin lymphoma, investigators find the drug is not cost-effective.

Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment

Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment

A nurse-led study explored the significance of nurse navigators for patients with lymphoma approaching their transition from acute care to survivorship care.

Newer Hodgkin Lymphoma Regimens Are Less Toxic, But Still Impose Reproductive Risks

Newer Hodgkin Lymphoma Regimens Are Less Toxic, But Still Impose Reproductive Risks

A substudy of a multinational study sought to determine the risk to ovarian function with ABVD, AVD, and BEACOPP regimens on ovarian function in women with Hodgkin lymphoma.

Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin

Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin

A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.

Rituximab Maintenance Improved Long-Term Survival in Elderly With Follicular Lymphoma

Rituximab Maintenance Improved Long-Term Survival in Elderly With Follicular Lymphoma

A retrospective analysis of outcomes demonstrated the influence of rituximab maintenance after R-CHOP or R-CVP for follicular lymphoma in elderly patients.

Insurance Status Influences Overall Survival in Follicular Lymphoma

Insurance Status Influences Overall Survival in Follicular Lymphoma

Outcomes data demonstrated the impact of socioeconomic status and insurance coverage on outcomes for patients with follicular lymphoma by age (younger than 65 and 65 and older).

RiBVD Effective in the First-Line Setting for Mantle Cell Lymphoma

RiBVD Effective in the First-Line Setting for Mantle Cell Lymphoma

Researchers sought to determine if the newly formed regimen RiBVD was effective and tolerable in patients older than 65 with mantle cell lymphoma.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs